Functional outcomes from a phase II study of a novel P2X7 receptor antagonist, AZD9056, in patients with active rheumatoid arthritis (CREATE Study).
Phase of Trial: Phase II
Latest Information Update: 01 Oct 2012
At a glance
- Drugs AZD 9056 (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
- Acronyms CREATE
- Sponsors AstraZeneca
- 01 Oct 2012 Results published in Annals of the Rheumatic Diseases.
- 20 Sep 2009 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History